EasyCookieInfo

Trieste – 16-18 October 2019. Takis participating at Meet in Italy for Life Sciences

Dr Luigi Aurisicchio, CEO/CSO at Takis Biotech has been invited at the workshop “Opportunità per Healthcare Innovative Startup” by the organizers to share its experience as finalist at EIT  Health Catapult competition.

EIT Health is a network of the most important innovators in the healthcare field supported by the EU.
- € 90 million of investments attracted by Startups, 400 supported Startups, 21,000 trained professionals and graduates, 35 solutions introduced on the market. The Workshop has presented programs for innovative Healthcare Startups to more mature companies, such as Takis Biotech.

READ MORE

 

Expertscape: the research on cancer vaccines of Takis is an excellence in Italy

The American platform Expertscape has included our CEO and CSO, Dr. Luigi Aurisicchio, in the list of top experts on cancer vaccines in Italy. He ranks  second in the list, and he becomes first considering only biotech companies and Rome and central Italy. The capital city, in particular, ranks third in Italy, confirming itself as a geographical center of excellence in biotech research against cancer.

 

Expertscape, designed by researchers from the University of North Carolina, is an independent rating platform, which bases its ranking on the number of publications by specialists in the various fields of medicine. Especially, studies published in the last decade are taken into consideration as well as the quality of the magazine, the position of the author within the article and the type of scientific work.

Aurisicchio has published 23 articles over the past 10 years dedicated to therapeutic vaccines against cancer. Its scientific production ranges from human to veterinary medicine and in recent years appears increasingly projected towards the future, which is that of precision medicine and personalized therapies.

"Takis represents excellence in the panorama of Italian biotechnology companies - declared Aurisicchio - in recent years we have undertaken many projects and we have dedicated ourselves to developing increasingly targeted and effective therapies against cancer. The merit is also and of our researchers, who put passion into what we do day after day to help patients in oncology ".

Congratulations to Luigi Aurisicchio for this prestigious award.

Link to Expertscape: http://www.expertscape.com/ex/cancer+vaccines/c/it

1 August 2019 – Takis awarded with the SME Instrument Phase 1

We are proud to announce that Takis biotech has been awarded with the SME Instrument Phase 1(ot EIC accelerator)  for its program on Neo-Antigen cancer vaccine, TK-Neo. The aim of the instrument is to fund disruptive ideas and transform them into concrete innovative solutions with European and global impact. The outcome of a phase 1 project is a feasibility report, including a more elaborated business plan.

The EIC Accelerator (SME Instrument) is a public funding programme that funds risk innovation in small businesses. It funds market-creating innovation in disruptive small businesses that have significant growth potential and global ambitions. The EIC Accelerator (SME Instrument) is part of Horizon 2020 – the EU's 80 billion € funding programme for Research and Innovation for 2014-2020.

Only the most innovative companies get selected. Until now, out of over 50.000 applicants 4500 companies have been funded. This shows how intense the competition is under the programme and demonstrates the high quality of the proposals funded. 25% of the companies funded under the EIC SME Instrument are in the 10% fastest growing companies in Europe according to Venture Radar.

We believe that TK-NEO has all the features for providing new therapies and changing cancer patients’ life!

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874958

 

18 July 2019 – Takis presents its innovation at “Health Technology and new algorithms for Artificial Intelligence”, Tecnopolo Tiburtino, Rome

Luigi Aurisicchio, CEO/CSO at Takis, has been invited to the event organized by Tecnopolo S.p.A and dedicated to Health Technology and Artificial Intelligence.

The meeting brings togheter companies and academic institutions involved in the study and experimentation of concrete technological solutions in medical field.

Dr. Aurisicchio will deliver a speech about Takis research in precision medicine, as we are developing a personalized cancer vaccine against tumor specific neoantigens (TK-NEO). This is a patient-tailored therapy with the potential to target metastatic and solid tumors, which we already validated in preclinical models.

For Registration:
https://health-technology-intelligenza-artificiale.eventbrite.it
Agenda allegata

Technological innovation has a great impact on health and medicine. This is where we make our contribution by implementing innovative individualized therapies based on the immune system against cancer and rare diseases.

 

4 July 2019 – Takis takes part in the event “Lazio2030: insieme per innovare”

Our CEO/CSO Luigi Aurisicchio has been invited to the event “Lazio2030: insieme per innovare”, because Takis is among the companies that have successfully used regional support to invest in research and innovation.

Since we have decided to invest and create innovation and employment in Lazio region, we have managed to keep the excellent reputation of Italian research by bringing new therapeutic solutions for cancer patients into pre-clinical and clinical stages.

To learn more about Takis’ Rever3mAb, MenHub, High Throughput mAbsclick here ...

To learn more about GENEVAX, led by Evvivax Spin off, click here ...

We are proud to have become part of this community and never going to stop believing in the value of scientific research.

 

4 June 2019 - Takis semifinalist at the European Health Catapult

Takis qualified as a semifinalist at the European Health Catapult organized by EIT Health with the support of the Health Axis Europe. This makes  us among the 14 best biotech companies in Europe!

EIT Health is a network of the best-in-class health innovators backed by the EU, aimed at ensuring a longer and healthier life for European citizens.

European Health Catapult is a training and competition programme that awards the best business concepts from medtech, biotech and digital health across Europe.

Dr Fabio Palombo, Head of Personalized Cancer Vaccine program, will attend the semi-finals in Delft from 24-26 September 2019, where we will participate in Training and Selection Days. This is a great opportunity for us to get high quality training in business plan modeling, deal negotiation and pitch as well as to extend our network and approach top level investors.

We are really looking forward to this amazing experience. We are ready to do our best to enhance Italian research in Europe.  

Read about: https://www.europeanhealthcatapult.eu/about/